Literature DB >> 21403021

Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes.

Núria Setó-Salvia1, Jordi Clarimón, Javier Pagonabarraga, Berta Pascual-Sedano, Antonia Campolongo, Onofre Combarros, Jose Ignacio Mateo, Daniel Regaña, Merce Martínez-Corral, Marta Marquié, Daniel Alcolea, Marc Suárez-Calvet, Laura Molina-Porcel, Oriol Dols, Teresa Gómez-Isla, Rafael Blesa, Alberto Lleó, Jaime Kulisevsky.   

Abstract

BACKGROUND: Dementia in Parkinson disease (PD) causes nursing home placement, caregiver distress, higher health care burden, and increased mortality.
OBJECTIVE: To determine whether the microtubule-associated protein tau (MAPT) H1 haplotype and MAPT subhaplotypes play a role in the risk of PD and Parkinson disease-dementia (PDD) complex.
DESIGN: Case-control genetic analysis.
SETTING: Movement Disorders and Memory Units, Hospital de Sant Pau, Barcelona, Spain. PARTICIPANTS: Two hundred two patients with PD (48 of whom developed dementia>2 years after disease onset), 41 patients with Lewy body dementia (LBD, pathologically confirmed in 17), 164 patients with Alzheimer disease (AD), and 374 controls.
METHODS: The MAPT haplotype was determined by testing for a 238-base pair deletion between exons 9 and 10, which is characteristic of the H2 haplotype. Haploview was used to visualize linkage disequilibrium relationships between all genetic variants (5 single-nucleotide polymorphisms and the del-In9 variant) within and surrounding the MAPT region.
RESULTS: The H1 haplotype was significantly overrepresented in PD patients compared with controls (P=.001). Stratifying the PD sample by the presence of dementia revealed a stronger association in PDD patients (sex- and age-adjusted odds ratio, 3.73; P=.002) than in PD patients without dementia (sex- and age-adjusted odds ratio, 1.89; P=.04). Examination of specific subhaplotypes showed that a rare version of the H1 haplotype (named H1p) was overrepresented in PDD patients compared with controls (2.3% vs 0.1%; P=.003). No positive signals for any of the MAPT variants or H1 subhaplotypes were found in AD or LBD.
CONCLUSIONS: Our data confirm that MAPT H1 is associated with PD and has a strong influence on the risk of dementia in PD patients. Our results also suggest that none of the MAPT subhaplotypes play a significant role in other neurodegenerative diseases, such as LBD or AD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21403021     DOI: 10.1001/archneurol.2011.17

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  57 in total

Review 1.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

Review 2.  Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

Authors:  Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre
Journal:  Mov Disord       Date:  2012-01-24       Impact factor: 10.338

3.  Clinical differences among mild cognitive impairment subtypes in Parkinson's disease.

Authors:  Jennifer G Goldman; Holly Weis; Glenn Stebbins; Bryan Bernard; Christopher G Goetz
Journal:  Mov Disord       Date:  2012-07-06       Impact factor: 10.338

Review 4.  Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.

Authors:  Jennifer G Goldman; Neelum T Aggarwal; Cynthia D Schroeder
Journal:  Neurodegener Dis Manag       Date:  2015-10-30

Review 5.  Mild cognitive impairment in Parkinson's disease.

Authors:  Saul Martinez-Horta; Jaime Kulisevsky
Journal:  J Neural Transm (Vienna)       Date:  2019-04-08       Impact factor: 3.575

6.  Association of MAPT H1 subhaplotypes with neuropathology of lewy body disease.

Authors:  Michael G Heckman; Koji Kasanuki; Rebecca R Brennan; Catherine Labbé; Emily R Vargas; Alexandra I Soto; Melissa E Murray; Shunsuke Koga; Dennis W Dickson; Owen A Ross
Journal:  Mov Disord       Date:  2019-06-24       Impact factor: 10.338

7.  Structural and functional characterization of H2 haplotype MAPT promoter: unique neurospecific domains and a hypoxia-inducible element would enhance rationally targeted tauopathy research for Alzheimer's disease.

Authors:  Bryan Maloney; Debomoy K Lahiri
Journal:  Gene       Date:  2012-01-30       Impact factor: 3.688

Review 8.  MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Authors:  Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub
Journal:  Mov Disord       Date:  2011-06-09       Impact factor: 10.338

9.  Dementia in long-term Parkinson's disease patients: a multicentre retrospective study.

Authors:  Jennifer Y Y Szeto; Courtney C Walton; Alexandra Rizos; Pablo Martinez-Martin; Glenda M Halliday; Sharon L Naismith; K Ray Chaudhuri; Simon J G Lewis
Journal:  NPJ Parkinsons Dis       Date:  2020-01-07

Review 10.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.